Banner

- - -

JOBS

EXECUTIVE JOBS

INVEST IN STOCKHOLM NEWSLETTER

SWEDISH WIRE NEWSLETTER

EMBASSIES/
CONSULATES
IN SWEDEN

RSS FEEDS

STOCKS

FLIGHTS, HOTELS AND HOLIDAYS

- - -
Investment opportunities

Tips from an insider: Five innovative tech startups

Tips from an insider: Stockholm tech start-ups

5 hot life science firms in Stockholm

Stockholm's top five infrastructure projects

Four Stockholm-based ICT firms to watch

Stockholm pioneers life science research

ICT startups offer investment opportunity

Swedish companies ready for exit

Five med-tech investment opportunities

Six cleantech investment opportunities

- - -
Rankings and surveys

Sweden tops English-language skills ranking

Sweden ranked world's best country to grow old

Swedish passport world's best for travellers

Sweden second best country for mothers

Stockholm climbs in competitiveness rankings

Sweden among best countries to be born

Fortune: 'Stockholm top place for startups'

Sweden tops first global Web Index

Sweden world's second most innovative country

Stockholm world's 6th 'best city'

'Cool Stockholm' most competitive Nordic capital

Sweden has (second) best reputation in the world

Sweden among top in Internet download speed

Sweden scores highest in 'Rule of law index'

Stockholm world's No1 in intellectual capital

Sweden the world's most ICT-competitive country

Sweden great place for moms – but Norway better

Swedes place 4th in English skills ranking

Sweden among top ICT countries

Sweden’s 10 greenest brands

‘Sweden needs to sell itself more’

Sweden overtakes the US in competitiveness

Sweden 10th ‘most admired country globally’

Sweden climbs in 'doing business' ranking

Sweden among world's least corrupt nations

Sweden's mortality rates world's second lowest

Sweden a good place to die – but Britain is best

Children in Sweden have best lives

Sweden the most competitive EU nation

Safe to do business with Swedes

How Sweden became an innovation frontrunner

Nordic countries world's most food-secure

Sweden the world’s best country – politically

Swedish firms among world's top brands

Swedish brands climb in global ranking

Sweden tops government ranking - while US lags 

'Swedish model' outranks 'American dream'  

Sweden among world's least corrupt nations

Orexo: Orexo announces that partner ProStrakan has presented strong sales figures for Abstral in Europe

Press release published at The Swedish Wire


Uppsala, January 7, 2010 - Orexo AB (STO: ORX) announces today that its partner ProStrakan Group plc (LSE: PSK) has presented its sales figures for Abstral in Europe in a press release. ProStrakan states that sales of Abstral underwent a strong development in 2009 and sales in the range of GBP 5 M - GBP 6 M were achieved for full-year. In ProStrakan's press release from November 2009, it was stated that sales for the first ten months of 2009 amounted to GBP 3.2 M.

Commenting on today's announcement, Torbjörn Bjerke, Orexo's President and CEO, said: "Abstral's sales growth is very strong in Europe and we can see that there is a large medical need to be met for cancer patients suffering from breakthrough pain. The increasing royalties are important in developing Orexo into a profitable pharmaceutical company."




For further information, contact:
Torbjörn Bjerke, President and CEO
Tel: +46 (0)708-66 19 90
E-mail: torbjorn.bjerke@orexo.com

Claes Wenthzel, Executive Vice President and CFO
Tel: +46 (0)708-620 122
E-mail: claes.wenthzel@orexo.com



About Abstral
Abstral is a fast-dissolving tablet for sublingual administration of fentanyl, intended for the management of breakthrough cancer pain in patients who are already receiving opioid analgesics. It is based on Orexo's unique and patented sublingual tablet technology in which a rapidly dissolving tablet is placed under the tongue and the active substance is absorbed by the mucous membrane. Currently Abstral is sold in Sweden, UK, Germany, Spain, Greece and France. An NDA for Abstral has been filed in the US by the partner ProStrakan and in Japan Abstral is being prepared for registration by the partner Kyowa Hakko Kirin.


About Orexo
Orexo is a pharmaceutical company focusing on developing treatments for pain and inflammation. The company has four products on the market as well as a broad project portfolio in late stages of development. Sales and product development are mainly carried out through worldwide partnership agreements with larger pharmaceutical companies. Orexo has 126 employees, and has its head office located in Uppsala, Sweden. More information can be found at www.orexo.com.



Note:
This is information that Orexo AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act and/or the Swedish Securities Markets Act. The information was provided for public release on 7th January, 2010 at 12:40 CET.



This information was distributed by Cision
 

Latest Jobs for English speakers in Sweden

Banner

Jobs for English speakers in Sweden

Banner
Ligatus RIGHT
Banner
AdP right SKY
Most Read Searched  
Banner
Banner
Banner